Physician profile
Laura Sullivan White
NPI 1144772153
$2,893.71
in general payments reported to CMS, 2019-2025
23 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.93 · 2023: $221 · 2024: $1,175 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $623.17 | 2023-2025 | |
| Lilly USA, LLC | $419.98 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $390.16 | 2023-2025 | |
| Novo Nordisk INC | $249.04 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $222.18 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Dexcom, INC. | $176.53 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.99 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $136.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $85.74 | 2024-2025 | |
| Glaxosmithkline, LLC. | $63.84 | 2024-2025 | Shingrix, Arexvy |
| Eisai INC. | $61.07 | 2024 | |
| Biogen, INC. | $50.76 | 2025 | Leqembi |
| Ardelyx, INC. | $46.58 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $34.25 | 2025 | Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.69 | 2024-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $24.06 | 2025 | Immulite 1000 Immunoassay System |
| Botanix Sb INC | $21.17 | 2025 | Sofdra |
| Inspire Medical Systems, INC. | $20.72 | 2025 | Inspire |
| Ibsa Pharma INC. | $19.56 | 2025 | Licart, Flector, Tirosint |
| Amgen INC. | $18.68 | 2024 | Repatha, Otezla |
| Averitas Pharma INC. | $17.52 | 2025 | Qutenza |
| Tris Pharma INC | $17.14 | 2024 | Dyanavel Xr |
| Lundbeck LLC | $16.16 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.